Northwest Biotherapeutics traded at $0.64 this Friday July 1st, increasing $0.01 or 1.57 percent since the previous trading session. Looking back, over the last four weeks, Northwest Biotherapeutics gained 6.45 percent. Over the last 12 months, its price fell by 56.32 percent. Looking ahead, we forecast Northwest Biotherapeutics to be priced at 0.67 by the end of this quarter and at 0.61 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.64
Daily Change
0.81%
Yearly
-56.65%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,691.00 -34.00 -0.59% -47.57%
Agenus 1.94 0 0% -64.86%
Applied Genetic Technologies 0.78 0.01 0.71% -81.18%
AstraZeneca 10,754.00 -46.00 -0.43% 22.50%
Bristol-Myers Squibb 76.57 -0.16 -0.21% 14.37%
Celldex Therapeutics 22.88 -4.09 -15.15% -32.42%
CTI Biopharma 6.05 0.08 1.26% 132.50%
CytrRx Corporation 0.10 0.01 7.19% -90.00%
Plus Therapeutics, Inc. 0.54 -0.002 -0.37% -77.67%
Genocea Biosciences 0.02 -0.002 -11.76% -99.33%
Infinity Pharmaceuticals 0.58 -0.05 -8.26% -79.72%
Merck & Co 92.43 1.26 1.38% 17.60%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Northwest Biotherapeutics 0.64 0.01 0.81% -56.65%
Pfizer 52.31 -0.12 -0.23% 31.66%
Roche Holding 320.40 1.85 0.58% -8.34%

Indexes Price Day Year
USND 11128 93.17 0.84% -23.99%
US2000 1728 20.57 1.20% -25.07%

Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to cover all solid tumor cancers in which the tumors can be surgically removed. It is on going Phase III trial for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company also offers a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.